EnteroMedics (RSLS)
(Delayed Data from NSDQ)
$0.18 USD
+0.01 (3.66%)
Updated Aug 12, 2024 09:53 AM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for ReShape Lifesciences Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 9 | 11 | 14 | 2 | 3 |
Cost Of Goods | 3 | 4 | 5 | 1 | 3 |
Gross Profit | 6 | 7 | 8 | 1 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 21 | 53 | 65 | 13 | 24 |
Income After Depreciation & Amortization | -15 | -46 | -57 | -12 | -23 |
Non-Operating Income | 4 | 0 | -5 | 0 | 0 |
Interest Expense | 0 | 0 | 1 | 0 | 0 |
Pretax Income | -11 | -47 | -62 | -12 | -24 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -11 | -46 | -62 | -12 | -24 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -11 | -46 | -62 | -12 | -24 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -15 | -44 | -54 | -11 | -22 |
Depreciation & Amortization (Cash Flow) | 0 | 2 | 2 | 1 | 1 |
Income After Depreciation & Amortization | -15 | -46 | -57 | -12 | -23 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 5.96 | 0.42 | 0.25 | 0.05 | 0.03 |
Diluted EPS Before Non-Recurring Items | -1.91 | -108.90 | -42.50 | -213.02 | -754.58 |
Diluted Net EPS (GAAP) | -1.91 | -108.90 | -250.00 | -238.52 | -754.58 |
Fiscal Year end for ReShape Lifesciences Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 1.94 | 1.98 | 2.16 | 2.25 |
Cost Of Goods | NA | 0.78 | 0.14 | 0.87 | 1.06 |
Gross Profit | NA | 1.17 | 1.84 | 1.29 | 1.19 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 3.37 | 3.74 | 5.17 | 5.17 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -2.20 | -1.90 | -3.88 | -3.98 |
Non-Operating Income | NA | 0.02 | 0.21 | 0.35 | 0.48 |
Interest Expense | NA | -0.01 | -0.02 | 0.00 | -0.01 |
Pretax Income | NA | -2.18 | -1.67 | -3.53 | -3.49 |
Income Taxes | NA | 0.01 | 0.03 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -2.19 | -1.70 | -3.53 | -3.49 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -2.19 | -1.70 | -3.53 | -3.49 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 23.46 | NA | 3.45 | 3.25 |
Diluted EPS Before Non-Recurring Items | NA | -0.09 | NA | -1.02 | -1.08 |
Diluted Net EPS (GAAP) | NA | -0.09 | 1.75 | -1.02 | -1.08 |